The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma

(2017) Giovanni Luca Gravina et al.   Journal of Hematology & Oncology

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

(2017) Ana-Alicia López-Iglesias et al.   Journal of Hematology & Oncology

Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial

(2017) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells

(2017) Leisi Zhang et al.   Targeted Oncology

The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models

(2017) Giovanni Luca Gravina et al.   TUMOR BIOLOGY

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways

(2017) L Besse et al.   Blood Cancer Journal

Role of PHLPP1 in inflammation response: Its loss contributes to gliomas development and progression

(2016) Da-Cai Teng et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Molecular dissection of the valproic acid effects on glioma cells

(2016) Sabine Hoja et al.   Oncotarget

The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101

(2015) Thomas Mehrling et al.   Anti-Cancer Agents in Medicinal Chemistry

Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites

(2015) Mona Darwish et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cyclooxygenase-2 inhibitor prevents radiation-enhanced infiltration of F98 glioma cells in brain of Fischer rat

(2015) Guillaume Desmarais et al.   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

How to train glioma cells to die: molecular challenges in cell death

(2015) Jeffrey Wojton et al.   JOURNAL OF NEURO-ONCOLOGY

Reversion of malignant phenotypes of human glioblastoma cells by β-elemene through β-catenin-mediated regulation of stemness-, differentiation- and epithelial-to-mesenchymal transition-related molecules

(2015) Tingzhun Zhu et al.   Journal of Translational Medicine

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

(2015) E. Q. Lee et al.   NEURO-ONCOLOGY

Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors

(2015) Brad Davis et al.   NEURO-ONCOLOGY

Epigenetic treatment of solid tumours: a review of clinical trials

(2015) Clara Nervi et al.   Clinical Epigenetics

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression

(2015) Gloria Perazzoli et al.   PLoS One

Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases

(2014) Eun Jung Choi et al.   BMC CANCER

Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors

(2014) Edward Pan et al.   JOURNAL OF NEURO-ONCOLOGY

Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine

(2014) Philipp Zimmer et al.   LEUKEMIA & LYMPHOMA

The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in Elderly Glioblastoma Patients: A Meta-Analysis

(2014) An-an Yin et al.   PLoS One

Epigenetics in radiotherapy: Where are we heading?

(2014) Kim M. Smits et al.   RADIOTHERAPY AND ONCOLOGY

Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells

(2013) Ming-Tsang Chiao et al.   Autophagy

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair

(2013) B Groselj et al.   BRITISH JOURNAL OF CANCER

HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells

(2013) Laurence Booth et al.   CANCER BIOLOGY & THERAPY

Efficacy of rapamycin against glioblastoma cancer stem cells

(2013) M. Mendiburu-Eliçabe et al.   Clinical & Translational Oncology

Drug Combinations with Proteasome Inhibitors in Antitumor Therapy

(2013) Laura Gatti et al.   CURRENT PHARMACEUTICAL DESIGN

PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer

(2013) Giovanni Luca Gravina et al.   ENDOCRINE-RELATED CANCER

Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway

(2013) Paul R. Gielen et al.   NEUROPHARMACOLOGY

Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

(2012) E. Q. Lee et al.   CLINICAL CANCER RESEARCH

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

(2012) Consolación Melguizo et al.   Journal of Translational Medicine

8733 POSTER Gossypol Induces Apoptosis and Synergize With Radiotherapy and Temzolomide in Glioblastoma Cells

(2011) C. Festuccia et al.   EUROPEAN JOURNAL OF CANCER

Salvage therapy with single agent bendamustine for recurrent glioblastoma

(2011) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

An in vivo patient-derived model of endogenous IDH1-mutant glioma

(2011) H. A. Luchman et al.   NEURO-ONCOLOGY

Sensitivity to temozolomide in brain tumor initiating cells

(2010) M. D. Blough et al.   NEURO-ONCOLOGY

Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas

(2010) A. Restrepo et al.   NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY